Nektar Therapeutics (Nasdaq: NKTR), a biopharmaceutical company, announced on Thursday its financial results for the full year ended 31 December 2019.
The company reported revenue for the year ended 31 December 2019 at USD114.6m as compared to USD1.2bn in 2018.
The firm posted total operating costs and expenses for 2019 at USD554.7m as compared to USD505.4m in 2018.
Net loss for the year ended 31 December 2019 was USD440.7m or USD2.52 diluted loss per share as compared to net income of USD681.3m or USD3.78 diluted earnings per share in 2018.
Howard W Robin, Nektar's president and CEO, commented, 'Nektar's progress over the past year has established a strong foundation for growth, with a robust portfolio of clinical-stage immuno-oncology and immunology candidates addressing multiple therapeutic areas.'
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government